Clinical Trial Update: A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity [Phase 2]

View source ↗

Summary

This document reports a Phase 2b dose-range finding study evaluating multiple doses of aleniglipron (GSBR-1290) for obesity/overweight with related comorbiditie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Aleniglipron (GSBR-1290)

Snippet

Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Conditions: Obesity, Overweight, or Chronic Weight Management | Phase 2 | Status: ACTIVE_NOT_RECRUITING